Clinical Trials Logo

Stage III Breast Cancer AJCC v7 clinical trials

View clinical trials related to Stage III Breast Cancer AJCC v7.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT02498613 Active, not recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Start date: August 31, 2016
Phase: Phase 2
Study type: Interventional

This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be removed by surgery (unresectable), including breast cancer, non-small cell lung cancer, small cell lung cancer, and pancreatic cancer. Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may also block the flow of oxygen to the tumor, and may help make the tumor more sensitive to olaparib.

NCT ID: NCT02414646 Active, not recruiting - Clinical trials for Stage IIIC Breast Cancer AJCC v7

Trastuzumab Emtansine in Treating Older Patients With Human Epidermal Growth Factor Receptor 2-Positive Stage I-III Breast Cancer

Start date: April 10, 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well trastuzumab emtansine works in treating older patients with human epidermal growth factor receptor 2 (HER2)-positive stage I-III breast cancer. HER2 is a protein found on the surface of cancer cells that helps them to grow and spread. Trastuzumab emtansine may kill cancer cells by binding to HER2-positive on the surface of the tumor cells and blocking their ability grow and spread.

NCT ID: NCT02311933 Active, not recruiting - Clinical trials for Recurrent Breast Carcinoma

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Start date: May 28, 2015
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well tamoxifen citrate works compared with z-endoxifen hydrochloride in treating patients with breast cancer that has spread to nearby tissue or lymph nodes or other parts of the body and has estrogen receptors but not human epidermal growth factor receptor 2 (HER2) receptors on the surface of its cells. Estrogen can cause the growth of tumor cells. Hormone therapy using tamoxifen citrate or z-endoxifen hydrochloride may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known whether tamoxifen citrate or z-endoxifen hydrochloride is more effective in treating patients with breast cancer.

NCT ID: NCT02079662 Active, not recruiting - Clinical trials for Stage IIIC Breast Cancer AJCC v7

The Role of Lifestyle Factors in Breast Cancer-Related Outcomes

Start date: June 13, 2013
Phase: N/A
Study type: Interventional

This randomized clinical trial studies an integrative oncology (making changes in lifestyle and behavior) program in improving cancer-related outcomes in patients with stage II or III breast cancer undergoing radiation therapy. An integrative oncology program consisting of dietary recommendations, physical activity, stress management, social support, and control of environmental contaminants may modify cancer-related biological processes, influence long-term treatment results, and improve the quality of life of patients.

NCT ID: NCT01638533 Active, not recruiting - Lymphoma Clinical Trials

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

Start date: June 12, 2012
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia, or solid tumors with liver dysfunction. Romidepsin may stop the growth of cancer cells by entering the cancer cells and by blocking the activity of proteins that are important for the cancer's growth and survival.

NCT ID: NCT01552434 Active, not recruiting - Malignant Neoplasm Clinical Trials

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Start date: March 16, 2012
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of bevacizumab and temsirolimus alone or in combination with valproic acid or cetuximab in treating patients with a malignancy that has spread to other places in the body or other disease that is not cancerous. Immunotherapy with bevacizumab and cetuximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as valproic acid, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether bevacizumab and temsirolimus work better when given alone or with valproic acid or cetuximab in treating patients with a malignancy or other disease that is not cancerous.

NCT ID: NCT01463072 Active, not recruiting - Clinical trials for Recurrent Breast Carcinoma

Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer

Start date: June 19, 2012
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects of nab-paclitaxel in treating older patients with breast cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or to other places in the body (metastatic). Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

NCT ID: NCT00576654 Active, not recruiting - Hodgkin Lymphoma Clinical Trials

Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery

Start date: December 5, 2007
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of veliparib when given together with irinotecan hydrochloride in treating patients with cancer that has spread to other parts of the body or that cannot be removed by surgery. Irinotecan hydrochloride can kill cancer cells by damaging the deoxyribonucleic acid (DNA) that is needed for cancer cell survival and growth. Veliparib may block proteins that repair the damaged DNA and may help irinotecan hydrochloride to kill more tumor cells. Giving irinotecan hydrochloride together with veliparib may kill more cancer cells.

NCT ID: NCT00496795 Active, not recruiting - Clinical trials for Stage III Breast Cancer AJCC V7

Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer

DDP
Start date: September 2007
Phase: Phase 2
Study type: Interventional

Molecular markers predicting response to dose dense chemotherapy with epirubicin and docetaxel in sequence for locally advanced breast cancer Protocol summary. Principal Investigator Hans P. Eikesdal, Professor, Dept. of Oncology, Haukeland University Hospital & Dept. of Clinical Science, University of Bergen Project leader: Professor Per Eystein Lønning, Dept. of Oncology, Haukeland University Hospital & Dept. of Clinical Science, University of Bergen Collaborators. Dept of Surgery - Responsible: Turid Aas, Consultant Surgeon Participants. Dept of Oncology Stephanie Geisler, Consultant Oncologist Jurgen Geisler, Consultant Oncologist Type of Study Phase II, Translational research Scientific aims: Addressing factors predicting response to dose intensive epirubicin followed by docetaxel sequential therapy Treatment regimen: epirubicin 60 mg/m2 on a 2 weekly basis x 4 followed by docetaxel 100 mg/m2 2-weekly x 4. Patients: Breast cancer patients below 65 years of age suffering from large (>4 cm largest diameter, non-inflammatory and / or N2-N3) primary breast cancer. . Clinical aim: Assessing responsiveness to this dose intensive regimen. Number of patients to be enrolled: 60 - 100